An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer

The third-generation aromatase inhibitors (AIS) are largely replacing tamoxifen in the adjuvant treatment of early-stage breast cancer in postmenopausal women with hormone receptor–positive tumours. To date, multiple trials have been conducted comparing tamoxifen treatment with an AI, and all have d...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, S., Sehdev, S., Joy, A., Madarnas, Y., Younus, J., Roy, J. A.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2009
Materias:
Medical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722048/
https://www.ncbi.nlm.nih.gov/pubmed/19672416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722048/
https://www.ncbi.nlm.nih.gov/pubmed/19672416

Ejemplares similares